[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
Wuttke
H
H
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg. t.eschenhagen@uke.uni-hamburg.de
Rau
T
T
Eschenhagen
T
T
D000317:Adrenergic alpha-Antagonists / Q000378:metabolism / Q000493:pharmacokinetics; D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000483:Alleles; D001262:Atenolol / Q000378:metabolism; D001578:Benzopyrans / Q000378:metabolism; D001711:Biotransformation; D017298:Bisoprolol / Q000378:metabolism; D002227:Carbazoles / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D000077261:Carvedilol; D002986:Clinical Trials as Topic; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D004983:Ethanolamines / Q000378:metabolism; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D009154:Mutation; D000068577:Nebivolol; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D011412:Propanolamines / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D012307:Risk Factors; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D002227:Carbazoles; D004983:Ethanolamines; D011412:Propanolamines; D000068577:Nebivolol; D000077261:Carvedilol; D001262:Atenolol; D019389:Cytochrome P-450 CYP2D6; D008790:Metoprolol; D017298:Bisoprolol